<DOC>
	<DOCNO>NCT00049556</DOCNO>
	<brief_summary>RATIONALE : Biological therapy gefitinib may interfere growth tumor cell slow growth cervical cancer . Comparing result diagnostic procedure perform , , treatment gefitinib may help doctor predict patient 's response treatment help plan effective treatment . PURPOSE : This phase II trial study well gefitinib work treat patient cervical cancer .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine reduction phosphorylation epidermal growth factor receptor ( EGFR ) , AKT , ERK proteomics tumor normal skin patient ovarian epithelial cancer cervical cancer receive gefitinib . ( Open accrual cervical cancer patient 4/5/2005 ) - Determine clinical activity drug patient . - Determine toxicity drug patient . - Correlate biologic modulation EGFR , ERK , AKT drug outcome toxic effect patient . - Correlate EGFR modulation skin outcome toxic effect patient treated drug . - Correlate expression EGFR phosphorylated-EGFR tissue biopsy patient biochemical modulation outcome . - Determine application surface-enhanced laser desorption ionization time-of-flight detection ( SELDI-TOF ) artificial intelligence bioinformatics serially obtain serum sample predict response toxic effect patient . OUTLINE : Patients stratify accord disease ( cervical cancer v ovarian epithelial , fallopian tube , primary peritoneal cancer ) . ( Open accrual cervical cancer patient 4/5/2005 ) Patients receive oral gefitinib daily . Treatment continue every 28 day absence disease progression unacceptable toxicity . Biopsies sentinel lesion ( CT guidance laparoscopy ) obtain baseline 4 week . Skin biopsy unaffected area also obtain time point . Tissue examine use immunohistochemical method . Proteomic profile use surface-enhanced laser desorption/ionization time-of-flight ( SELDI-TOF ) mass spectrometry conduct serum baseline every 4 week . Patients follow monthly . PROJECTED ACCRUAL : A total 30-40 patient ( 15-20 per stratum ) accrue study within 10-12 month . ( Open accrual cervical cancer patient 4/5/2005 )</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial cancer cervical cancer ( open accrual cervical cancer patient 4/5/2005 ) Relapsed refractory The following also eligible : ( open accrual cervical cancer patient 4/5/2005 ) Cancer fallopian tube Primary peritoneal cancer Cancer low malignant potential invasive recurrence Block recuts primary tumor recent resection specimen metastatic site require Measurable disease sentinel lesion adequate core biopsy percutaneous biopsy laparoscopy No CNS involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hepatic Bilirubin le 1.5 mg/dL AST ALT great 2.5 time upper limit normal Renal Creatinine le 1.5 mg/dL Cardiovascular No myocardial infarction within past 6 month No unstable dysrhythmia within past 6 month Other No invasive malignancy within past 5 year except noninvasive nonmelanoma skin cancer No active ocular inflammation infection No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy No prior cetuximab monoclonal antibody ABXEGF Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy At least 4 week since prior hormonal therapy recover No concurrent tamoxifen Radiotherapy At least 4 week since prior radiotherapy recover Surgery Recovered prior oncologic major surgery Other No prior epidermal growth factor receptor inhibitory agent ( e.g. , OSI774 ) No concurrent antiretroviral therapy No concurrent itraconozole , ketoconazole , erythromycin , verapamil , chlorpromazine , amiodarone , chloroquine No concurrent drug know induce CYP3A4 enzyme ( e.g. , phenytoin , carbamazepine , rifampicin , barbiturate , oxacarbazepine , rifapentine , Hypericum perforatum )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>